Dyne Therapeutics Files PRE 14A Proxy on Apr 9 Dyne Therapeutics filed a Form PRE 14A on Apr 9, 2026 (Investing.com/SEC), signaling upcoming governance votes—review the definitive proxy and EDGAR for proposal specifics.

Dyne Therapeutics Files PRE 14A Proxy on Apr 9: Dyne Therapeutics filed a Form PRE 14A on Apr 9, 2026 (Investing.com/SEC), signaling upcoming governance votes—review the definitive proxy and EDGAR for… 👈 Read full analysis #DyneTherapeutics #PRE14A #GovernanceVotes #InvestmentNews #ProxyStatement

📄Estos datos fueron presentados en una presentación de póster de última hora en la Conferencia Clínica y Científica 2026 de la MDA, que se llevo a cabo del 8 al 11 de marzo de 2026, en Orlando, Florida

🔗Lee el artículo completo en el link: lnkd.in/eXS2jzhF

#TheAkariFoundation #DyneTherapeutics

🔗Lee el artículo completo en el siguiente link: theakarifoundation-pr.org/blog

Da clic en el link de nuestro perfil y visita nuestros ARTÍCULOS más recientes.

#TheAkariFoundation #enfermedadesraras #DistrofiaMuscularDeDuchenne #DyneTherapeutics #DELIVER #somoselcorazóndeladistrofia #AkariEnero

Proud to partner with #DyneTherapeutics and #EngageHealthInc at #NORDSummit 💙 Together we shared early findings from our Health Insurance Literacy in #myotonicDystrophy Type 1 (DM1) study—highlighting how collaboration helps move research forward and strengthens the #RareDisease community.

Se espera que la designación acelere el desarrollo y la revisión regulatoria de medicinas orientadas a tratar condiciones serias.🤝📑

🔗Lee el artículo completo en el siguiente link: lnkd.in/e6hHkmYD

#TheAkariFoundation #enfermedadesraras #DistrofiaMuscularDeDuchenne #DyneTherapeutics

Dyne Therapeutics stock rises after FDA grants breakthrough therapy status Investing.com -- Dyne Therapeutics Inc (NASDAQ:DYN) stock rose 3.6% after the company announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to its DYNE-251 treatment for Duchenne muscular dystrophy (DMD) patients amenable to exon 51 skipping. The designation was based on data from the company’s ongoing DELIVER clinical trial. The breakthrough status provides Dyne with enhanced FDA support, including senior-level involvement, early and frequent communication with FDA reviewers, and eligibility for rolling and priority review, potentially reducing the review timeline from 12 to 8 months. "This Breakthrough Therapy Designation for DYNE-251 is a testament to its potential as a next-generation therapy designed to bring meaningful functional improvement to individuals with DMD for whom exon 51 skipping can lead to the production of near full-length dystrophin," said Doug Kerr, chief medical officer of Dyne. The company reported that DYNE-251 has demonstrated sustained functional improvement through 18 months, as assessed by key measures such as time to rise and stride velocity 95th centile. This marks the second breakthrough therapy designation for Dyne’s lead programs, with DYNE-101 having received the same status for myotonic dystrophy type 1 earlier this year. Dyne has completed enrollment of 32 patients in the Registrational Expansion Cohort of the DELIVER trial, with data expected in late 2025. The company anticipates a potential Biologics License Application submission for U.S. Accelerated Approval in early 2026. DYNE-251 has also received Fast Track, Orphan Drug, and Rare Pediatric disease designations from the FDA and Orphan Drug designation from the European Medicines Agency for DMD treatment. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Don't miss out on the next big opportunity! Stay ahead of the curve with ProPicks AI – 6 model portfolios fueled by AI stock picks with a stellar performance this year... In 2024 alone, ProPicks AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. That's an impressive track record. With portfolios tailored for Dow stocks, S&P stocks, Tech Stocks, and Mid Cap stocks, you can explore various wealth-building strategies. So if DYN is on your watchlist, it could be very wise to know whether or not it made the ProPicks AI lists.

Click Subscribe #DyneTherapeutics #StockMarket #FinanceNews #BreakthroughTherapy #FDA

Dyne Therapeutics stock falls after updated plan for accelerated approval in DM1 Investing.com -- Dyne Therapeutics, Inc. (Nasdaq:DYN) stock fell 23% after the company announced an updated plan for obtaining U.S. Accelerated Approval for DYNE-101 in myotonic dystrophy type 1 (DM1) following a Type C meeting with the FDA. The clinical-stage neuromuscular disease company revealed that the FDA has granted Breakthrough Therapy Designation to DYNE-101 for the treatment of DM1. Based on FDA feedback and analysis of new long-term functional data, Dyne has submitted a revised protocol for the ongoing Registrational Expansion Cohort of the ACHIEVE trial with video hand opening time (vHOT) as the primary endpoint for potential Accelerated Approval. According to the updated timeline, Dyne plans to complete enrollment in the Registrational Expansion Cohort in Q4 2025, with data expected by mid-2026 to support a potential U.S. Accelerated Approval submission in late 2026. The company also plans to initiate a confirmatory Phase 3 clinical trial in the first quarter of 2026. The revised protocol for the Registrational Expansion Cohort includes a primary endpoint measuring change from baseline in middle finger myotonia using vHOT at 6 months compared to placebo. Secondary endpoints include changes in splicing, muscle strength, performance tests, and patient-reported outcomes. The cohort is expected to enroll 60 participants randomized 3:1 to receive DYNE-101 or placebo. Dyne also reported new long-term data from the multiple ascending dose portion of the ACHIEVE trial, showing sustained improvement in myotonia and other endpoints at 12 months for patients receiving the registrational dose of 6.8 mg/kg Q8W. The company expects its cash, cash equivalents and marketable securities as of March 31, 2025, totaling $677.5 million, will fund operations into the fourth quarter of 2026. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Should you invest $2,000 in DYN right now? Before you buy stock in DYN, consider this: ProPicks AI are 6 easy-to-follow model portfolios created by Investing.com for building wealth by identifying winning stocks and letting them run. Over 150,000 paying members trust ProPicks to find new stocks to buy – driven by AI. The ProPicks AI algorithm has just identified the best stocks for investors to buy now. The stocks that made the cut could produce enormous returns in the coming years. Is DYN one of them?

Click Subscribe #DyneTherapeutics #DM1 #StockMarket #Investing #FDA

#DyneTherapeutics myotonic dystrophy type I regulatory update likely coming tomorrow.

These pathway updates have been major biotech stock movers recently. If no big move on day 1, following days usually strong upward momentum.

investors.dyne-tx.com/news-release...

Click Subscribe #DyneTherapeutics #StockMarket #OrphanDrug #PharmaNews #Biotech